

Date: 28 May 2025

To

The Secretary <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 <b>Scrip Code: 544293</b>	The Secretary <b>The National Stock Exchange of India Limited</b> Exchange Plaza, Plot No. C/1 G Block Bandra -Kurla Complex, Bandra (East) Mumbai- 400 051 <b>Scrip Symbol: SURAKSHA</b>
---	--

Dear Sir / Ma'am,

**Sub: Outcome of the Board meeting held today i.e. Wednesday, 28 May 2025**

**Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') as amended from time to time**

With further reference to our letter dated 21 May 2025, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. on Wednesday, 28 May 2025, has *inter alia*, considered and **approved** the following matters:

1. Audited (standalone and consolidated) financial results of the Company for the quarter and financial year ended 31 March 2025 along with Auditor's Report thereon, issued by the Statutory Auditors of the Company, Statement of Assets and Liabilities as at 31 March 2025 and Statement of Cash Flow, in terms of Regulation 33 of the Listing Regulations, enclosed herewith as **Annexure-1**.

Further, pursuant to the third proviso of Regulation 33(3)(d) of the Listing Regulations, a declaration of **Unmodified Opinion** signed by the Chief Executive Officer and Chief Financial Officer of the Company, in respect of the audited (standalone and consolidated) financial results of the Company for the financial year ended 31 March 2025, is enclosed herewith as **Annexure-2**.

2. Notice convening the 20th Annual General Meeting of the Company scheduled to be held on Friday, 05 September 2025 for the financial year 2024-25.
3. Appointment of M/s Pramod Agarwal & Co. (Firm Registration No.: S2002WB057700; Peer Review: 977/2020), Practicing Company Secretaries, as Secretarial Auditor to conduct the secretarial audit of the Company for a term of five (5) consecutive financial years i.e. from FY 2025-26 upto FY 2029-30, subject to the approval of shareholders of the Company at the ensuing Annual General Meeting.
4. Re-appointment of M/s Bihani Rashmi & Co. (Firm Registration No.: 328058E), Practicing Chartered Accountants, as Internal Auditor to conduct the internal audit of the Company for the FY 2025-26.
5. Re-appointment of M/s. S Chhaparia & Associates, (Firm Registration No.: 101591), Cost and Management Accountant, as Cost Auditor to conduct the audit of the cost account records of the

Company for all the applicable products for the FY 2025-26, subject to ratification of remuneration by the shareholders at the ensuing Annual General Meeting.

The relevant details regarding the appointments and re-appointments referred to in item no. 3 to 5 above, as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024, are enclosed as **Annexure-3**.

The meeting of the Board of Directors commenced at 2.00 pm (IST) and concluded at 6.30 pm (IST).

You are requested to kindly take the same on record.

**For Suraksha Diagnostic Limited**

---

**Mamta Jain**  
**Company Secretary & Compliance Officer**

**Encl:** As above

**Independent Auditor's Report on Standalone Audited Annual Financial Results of Suraksha Diagnostic Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To The Board of Directors of Suraksha Diagnostic Limited**

**Report on the Audit of Standalone Annual Financial Results**

**Opinion**

We have audited the accompanying statement of standalone annual financial results of **Suraksha Diagnostic Limited** (hereinafter referred to as 'the Company') for the year ended March 31, 2025 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- (i) is presented in accordance with the requirements of the Listing Regulations in this regard; and
- (ii) gives a true and fair view, in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit, and other comprehensive income and other financial information of the Company for the year ended March 31, 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



### **Management and Board of Directors' Responsibilities for the Standalone Audited Annual Financial Results**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit, and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended, issued thereunder and other accounting principles generally accepted in India and is in compliance with the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the financial reporting process of the Company.

### **Auditors' Responsibilities for the Audit of the Standalone Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.





- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matter:

1. The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matter.

2. The Statement includes the results for the corresponding quarter ended March 31, 2024 which have been compiled by the management and have not been subject to review or audit by us or by any other auditor.



# MSKA & Associates

Chartered Accountants

Our opinion is not modified in respect of the above matter.

For M S K A & Associates  
Chartered Accountants  
ICAI Firm Registration No.105047W

  
Dipak Jaiswal  
Partner



Membership No. 063682  
UDIN: 25063682BMOTOU7695

Place: Kolkata  
Date: May 28, 2025

Suraksha Diagnostic Limited  
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India  
(CIN : L85110WB2005PLC102265)  
Website : www.surakshanet.com

Statement of standalone financial results for the quarter and year ended 31 March 2025

(₹ in lakhs)

Particulars	Quarter ended			Year ended	Year ended
	31 March 2025 (refer note 3)	31 December 2024 (Unaudited)	31 March 2024 (refer note 4)	31 March 2025 (Audited)	31 March 2024 (Audited)
Income					
Revenue from operations	6,414.51	5,857.00	5,537.04	24,909.54	21,852.47
Other income	94.21	97.45	105.45	438.30	364.76
<b>Total Income</b>	<b>6,508.72</b>	<b>5,954.45</b>	<b>5,642.49</b>	<b>25,347.84</b>	<b>22,217.23</b>
Expenses					
Cost of materials consumed	858.89	598.82	655.32	2,894.54	2,712.66
Employee benefits expenses	999.52	1,101.42	885.44	4,190.58	3,963.93
Finance costs	206.33	203.29	212.30	838.53	878.83
Depreciation and amortisation expense	865.93	861.55	832.81	3,472.83	3,256.70
Impairment Loss	80.23	88.20	19.99	218.58	13.42
Other expenses	2,493.76	2,259.27	1,984.01	9,346.81	8,043.29
<b>Total expenses</b>	<b>5,504.66</b>	<b>5,112.55</b>	<b>4,589.87</b>	<b>20,961.87</b>	<b>18,868.83</b>
<b>Profit before tax and exceptional items</b>	<b>1,004.06</b>	<b>841.90</b>	<b>1,052.62</b>	<b>4,385.97</b>	<b>3,348.40</b>
Exceptional items	-	-	77.88	-	77.88
<b>Profit before tax</b>	<b>1,004.06</b>	<b>841.90</b>	<b>974.74</b>	<b>4,385.97</b>	<b>3,270.52</b>
Income tax expense					
Current tax	184.53	215.41	285.76	1,066.83	946.46
Tax pertaining to earlier years	(38.22)	-	-	(38.22)	-
Deferred tax	57.08	(9.20)	4.87	13.36	(114.33)
<b>Total tax expense</b>	<b>203.39</b>	<b>206.21</b>	<b>290.63</b>	<b>1,041.97</b>	<b>832.13</b>
<b>Profit for the period/year</b>	<b>800.67</b>	<b>635.69</b>	<b>684.11</b>	<b>3,344.00</b>	<b>2,438.39</b>
Other comprehensive income					
Items that will not be reclassified subsequently to profit or loss					
Remeasurement gain/(loss) of net defined benefit plan	(8.47)	16.35	(19.19)	(27.25)	(19.19)
Income tax effect on above	2.13	(4.11)	4.83	6.86	4.83
<b>Other comprehensive income/(losses) for the period/year, net of tax</b>	<b>(6.34)</b>	<b>12.24</b>	<b>(14.36)</b>	<b>(20.39)</b>	<b>(14.36)</b>
<b>Total comprehensive income for the period/year</b>	<b>794.33</b>	<b>647.93</b>	<b>669.75</b>	<b>3,323.61</b>	<b>2,424.03</b>
<b>Paid-up equity share capital (face value - ₹ 2 per share)</b>				<b>1,041.62</b>	<b>690.00</b>
<b>Other equity</b>				<b>20,389.60</b>	<b>17,233.63</b>
<b>Earnings per equity share ( Face Value of ₹ 2 each)</b>					
- Basic (Rs) (not annualised except for year end figures)	1.54	1.22	1.28	6.42	4.57
- Diluted (Rs) (not annualised except for year end figures)	1.54	1.22	1.28	6.42	4.57



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

### Notes to the audited standalone financial results

1. The standalone financial results for the quarter and financial year ended 31 March 2025 ("the financial results") of Suraksha Diagnostic Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the regulations").
2. These financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 28 May 2025. These financial results for the year ended 31 March 2025 have been audited by the statutory auditor and they have issued an unmodified opinion.
3. The standalone figures for the quarter ended 31 March 2025 are the balancing figures between the audited standalone figures in respect of the full financial year and the published unaudited year to date standalone figures up to the third quarter of the financial year.
4. The figures for the quarter ended 31 March 2024 are presented based on the information complied by the management in accordance with Ind AS and have not been subject to review or audit by the statutory auditors or by any other auditor. However, the management has prepared the results for the said period by applying consistent accounting policies.
5. During the year ended 31 March 2025, the Company has completed an Initial Public Offering entirely as offer for sale of 1,91,89,330 equity shares by existing share holders with face value of ₹.2 and listed on both National Stock exchange (NSE) and Bombay Stock Exchange (BSE) on December 06, 2024.
6. During the year ended 31 March 2025, 0.0001% Compulsorily Convertible Preference Shares aggregating to 1,62,859 preference shares of par value ₹ 100/- each were converted into 89,55,761 equity shares of par value of ₹ 2/- each.
7. During the year ended 31 March 2025, the Nomination and Remuneration Committee ("the NRC") had approved grant of 2,08,164 stock options to employees under the Suraksha Employee Stock Option Scheme 2024 ("the Scheme"). The Company has accounted for these stock options in accordance with Ind AS 102 – Share-Based Payments.
8. The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 – "Operating Segments".
9. During the quarter ended 31 March 2025, the Company had entered into a Share Subscription Agreement for subscribing to 95,841 equity shares of ₹10/- each representing 16.17% of the total equity share capital of Fetomat Wellness Private Limited ('Fetomat'). Subsequent to financial year ended 31 March 2025, the Company had entered into Share Purchase Agreements ('SPA's') with existing shareholders of Fetomat for acquisition of 2,77,582 equity shares of ₹10/- each representing 46.83% of the total equity share capital of Fetomat, resulting in Fetomat becoming a subsidiary of the Company.
10. These financial results are also available on the Company's website ([www.surakshanet.com](http://www.surakshanet.com)) and on the stock exchange websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)).
11. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.



For and on behalf of Board of Directors of  
Suraksha Diagnostic Limited

  
Dr. Somnath Chatterjee  
Chairman & Joint Managing Director  
DIN: 00137075

Place: Kolkata  
Date: 28 May 2025



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: [info@surakshanet.com](mailto:info@surakshanet.com) | Website: [www.surakshanet.com](http://www.surakshanet.com)

Phone: (033) 66059750 | CIN : [085110WB2005PLC102265](https://www.bseindia.com/cin/085110WB2005PLC102265)



# Suraksha

## Clinic & Diagnostics

Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India

(CIN : L85110WB2005PLC102265)

Website : [www.surakshanet.com](http://www.surakshanet.com)

Standalone Statement of Assets and Liability as at 31 March 2025

(₹ in lakhs)

Particulars	As at 31 March 2025 (Audited)	As at 31 March 2024 (Audited)
<b>Assets</b>		
<b>Non-current assets</b>		
Property, plant and equipment	13,938.29	13,492.83
Capital work-in-progress	532.03	101.64
Right-of-use assets	7,429.02	7,540.89
Other intangible assets	148.00	107.10
Intangible assets under development	49.34	-
<b>Financial assets</b>		
Investments	271.48	115.74
Loans	1,387.23	552.14
Other financial assets	4,263.66	839.55
Non-current tax assets (net)	161.31	181.68
Other non-current assets	702.61	166.85
<b>Total non-current assets</b>	<b>28,882.97</b>	<b>23,098.42</b>
<b>Current assets</b>		
Inventories	801.65	665.31
<b>Financial assets</b>		
Trade receivables	1,505.80	915.20
Cash and cash equivalents	147.54	210.94
Bank balances other than cash and cash equivalents	1,405.31	5,069.88
Other financial assets	252.17	-
Other current assets	314.59	214.78
<b>Total current assets</b>	<b>4,427.06</b>	<b>7,076.11</b>
<b>Total Assets</b>	<b>33,310.03</b>	<b>30,174.53</b>
<b>Equity and Liabilities</b>		
<b>Equity</b>		
Equity share capital	1,041.62	690.00
Instruments entirely equity in nature	-	162.86
Other equity	20,389.60	17,233.63
<b>Total equity</b>	<b>21,431.22</b>	<b>18,086.49</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
Borrowings	287.54	518.31
Lease liabilities	7,122.81	7,030.65
Provisions	102.22	77.13
Deferred tax liabilities (net)	545.09	538.59
<b>Total non-current liabilities</b>	<b>8,057.66</b>	<b>8,164.68</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
Borrowings	294.98	345.35
Lease liabilities	1,183.76	1,153.32
Trade payables		
Total outstanding dues of micro enterprises and small enterprises	196.74	321.80
Total outstanding dues other than above micro enterprises and small enterprises	1,202.11	1,107.75
Other financial liabilities	713.25	773.73
Other current liabilities	217.79	170.01
Provisions	12.52	-
Current tax liabilities (net)	-	51.40
<b>Total current liabilities</b>	<b>3,821.15</b>	<b>3,923.36</b>
<b>Total liabilities</b>	<b>11,878.81</b>	<b>12,088.04</b>
<b>Total equity and liabilities</b>	<b>33,310.03</b>	<b>30,174.53</b>



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: [info@surakshanet.com](mailto:info@surakshanet.com) | Website: [www.surakshanet.com](http://www.surakshanet.com)

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

# Suraksha

## Clinic & Diagnostics

Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India

(CIN : L85110WB2005PLC102265)

Website : www.surakshanet.com

Standalone Statement of Cash Flows for the year ended 31 March 2025

(₹ in lakhs)

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
<b>Cash flow from operating activities</b>		
Profit before tax	4,385.97	3,270.52
Adjustments for:		
Depreciation and amortisation expense	3,472.82	3,256.70
Finance costs	838.53	878.83
Interest on loans, deposits and IT refund	(380.77)	(331.71)
Unwinding of security deposit	(33.40)	(29.71)
Exceptional items	-	77.88
Loss on sale of property, plant and equipment	25.41	214.52
Impairment Loss	218.58	13.42
Security deposits written off	6.65	-
Bad debts written off	26.78	40.23
Share based payment expenses	21.11	-
Liabilities/ provisions no longer required written back	(22.97)	-
<b>Operating profit before working capital changes</b>	<b>8,558.71</b>	<b>7,390.68</b>
<b>Changes in operating assets and liabilities</b>		
Adjustments for (Increase) / decrease in operating assets		
Trade receivables	(818.08)	(500.12)
Inventories	(136.34)	(61.10)
Other financial assets	(308.54)	52.57
Other current assets	(99.81)	15.11
Adjustments for Increase / (decrease) in operating liabilities		
Trade payables	(7.73)	49.03
Other current liabilities	47.92	48.52
Other financial liabilities	90.95	(16.79)
Provisions	10.36	4.97
<b>Cash generated from operations</b>	<b>7,337.44</b>	<b>6,982.87</b>
Income tax paid (net)	(1,057.64)	(859.87)
<b>Net cash flows generated from operating activities (A)</b>	<b>6,279.80</b>	<b>6,123.00</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant & equipment, other intangible assets and Intangible Asset under Development (including capital work-in-progress, capital advances and capital	(3,538.85)	(4,221.70)
Proceeds from sale of property, plant & equipment	14.95	255.18
Net Redemption in deposits with banks	174.16	653.96
Investment in Subsidiary/Other Company	(155.74)	(65.74)
Loan given to Subsidiaries	(748.32)	(444.00)
Interest received on bank deposits	325.40	318.57
<b>Net cash flows used in investing activities (B)</b>	<b>(3,928.40)</b>	<b>(3,503.73)</b>
<b>Cash flow from financing activities</b>		
Proceeds of borrowings	-	50.00
Repayment of borrowings	(281.14)	(586.88)
Payment of lease liabilities	(2,069.99)	(1,955.47)
Finance cost paid	(63.67)	(90.77)
<b>Net cash flows used in financing activities (C)</b>	<b>(2,414.80)</b>	<b>(2,583.12)</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>(63.40)</b>	<b>36.15</b>
Cash and cash equivalents at the beginning of the period	210.94	174.79
<b>Cash and cash equivalents at the end of the period</b>	<b>147.54</b>	<b>210.94</b>



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

**Independent Auditor's Report on Consolidated Audited Annual Financial Results of the Suraksha Diagnostic Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.**

**To the Board of Directors of Suraksha Diagnostic Limited**

**Report on the Audit of Consolidated Annual Financial Results**

**Opinion**

We have audited the accompanying Statement of Consolidated annual financial results of **Suraksha Diagnostic Limited** (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended March 31, 2025 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').


In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditor on separate audited financial statements of the subsidiaries, the aforesaid Statement:

(i) includes the consolidated audited annual financial results of Holding Company and the following entities to indicate list of entities included in the consolidation:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Suraksha Speciality LLP	Subsidiary
2	Suraksha Salvia LLP	Step-down Subsidiary
3	Suraksha Radiology Private Limited	Subsidiary Company
4	Suraksha Advanced Radiology Private Limited	Subsidiary Company
5	Asian Institute of Immunology and Rheumatology LLP	Subsidiary

(ii) is presented in accordance with the requirements of the Listing Regulations in this regard; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit, and other comprehensive income and other financial information of the Group, for the year ended March 31, 2025.



### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

### **Management and Board of Directors' Responsibilities for the Consolidated Audited Annual Financial Results**

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit, and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in accordance with the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors/ Management of the companies/entities included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors/ Management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies/ management of the companies/entities included in the Group are responsible for overseeing the financial reporting process of the Group.





### **Auditors' Responsibilities for the Audit of the Consolidated Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements/financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.





We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

**Other Matters:**

1. The Statement includes the audited financial results of five (5) subsidiaries, whose Financial Statements reflect Group's share of total assets of Rs. 2043.83 lakhs as at March 31, 2025, Group's share of total revenue of Rs 460.14 lakhs, Group's share of total net profit after tax of Rs. (246.55) lakhs, and other comprehensive income of Rs. (246.55) lakhs for the period from April 1, 2024 to March 31, 2025 and Group's net cash inflow of Rs. 36.07 lakhs for the year ended as on date respectively, as considered in the Statement, which have been audited by the other auditors whose reports on financial statements of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these Subsidiaries, is based solely on the reports of such other auditors and the procedures performed by us are as stated in paragraph above.

Our opinion is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

2. The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matter.

3. The Statement includes the results for the corresponding quarter ended March 31, 2024 which have been compiled by the management and have not been subject to review or audit by us or by any other auditor.



# MSKA & Associates

Chartered Accountants

Our opinion is not modified in respect of the above matter.

**For M S K A & Associates**

Chartered Accountants

ICAI Firm Registration No.105047W



Dipak Jaiswal

Partner

Membership No.: 063682

UDIN: 25063682BMOTOW9086



**Place:** Kolkata

**Date:** May 28<sup>th</sup>, 2025

# Suraksha

## Clinic & Diagnostics

Suraksha Diagnostic Limited  
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India  
(CIN : L85110WB2005PLC102265)  
Website : www.surakshanet.com

### Statement of consolidated financial result for the quarter and year ended 31 March 2025

	Quarter ended			Year ended	
Particulars	31 March 2025 (refer note 3)	31 December 2024 (Unaudited)	31 March 2024 (refer note 4)	31 March 2025 (Audited)	31 March 2024 (Audited)
<b>Income</b>					
Revenue from operations	6,509.47	5,951.30	5,518.80	25,209.27	21,870.85
Other income	81.68	59.91	97.93	384.60	355.09
<b>Total Income</b>	<b>6,591.15</b>	<b>6,011.21</b>	<b>5,616.73</b>	<b>25,593.87</b>	<b>22,225.94</b>
<b>Expenses</b>					
Cost of materials consumed	884.80	610.32	657.66	2,951.91	2,725.12
Employee benefits expenses	1,020.34	1,128.66	899.66	4,289.03	4,006.81
Finance costs	206.33	198.15	207.79	838.53	878.83
Depreciation and amortisation expense	872.88	882.72	835.91	3,529.77	3,259.80
Impairment Loss	80.23	88.20	19.99	218.58	13.42
Other expenses	2,605.32	2,298.49	1,994.60	9,625.52	8,118.83
<b>Total expenses</b>	<b>5,669.90</b>	<b>5,206.54</b>	<b>4,615.61</b>	<b>21,453.34</b>	<b>19,002.81</b>
<b>Profit before tax and exceptional items</b>	<b>921.25</b>	<b>804.67</b>	<b>1,001.12</b>	<b>4,140.53</b>	<b>3,223.13</b>
Exceptional items	-	-	77.88	-	77.88
<b>Profit before tax</b>	<b>921.25</b>	<b>804.67</b>	<b>923.24</b>	<b>4,140.53</b>	<b>3,145.25</b>
<b>Income tax expense</b>					
Current tax	185.30	215.41	286.26	1,067.60	946.96
Tax pertaining to earlier years	(38.22)	-	-	(38.22)	-
Deferred tax	57.08	(9.20)	4.87	13.36	(114.33)
<b>Total tax expense</b>	<b>204.16</b>	<b>206.21</b>	<b>291.13</b>	<b>1,042.74</b>	<b>832.63</b>
<b>Profit for the period/year</b>	<b>717.09</b>	<b>598.46</b>	<b>632.11</b>	<b>3,097.79</b>	<b>2,312.62</b>
<b>Other comprehensive income</b>					
Items that will not be reclassified subsequently to profit or loss					
Remeasurement gain/(loss) of net defined benefit plan	(8.47)	16.35	(19.19)	(27.25)	(19.19)
Income tax effect on above	2.13	(4.11)	4.83	6.86	4.83
<b>Other comprehensive income/(losses) for the period/ year, net of tax</b>	<b>(6.34)</b>	<b>12.24</b>	<b>(14.36)</b>	<b>(20.39)</b>	<b>(14.36)</b>
<b>Total comprehensive income for the period/year</b>	<b>710.75</b>	<b>610.70</b>	<b>617.75</b>	<b>3,077.40</b>	<b>2,298.26</b>
<b>Profit for the period/year attributed to</b>					
Owners of the parent	738.87	615.36	652.05	3,182.41	2,362.54
Non- controlling interests	(21.78)	(16.90)	(19.94)	(84.62)	(49.92)
	<b>717.09</b>	<b>598.46</b>	<b>632.11</b>	<b>3,097.79</b>	<b>2,312.62</b>
<b>Other comprehensive income for the period/year attributable to</b>					
Owners of the parent	(6.34)	12.24	(14.36)	(20.39)	(14.36)
Non- controlling interests	-	-	-	-	-
	<b>(6.34)</b>	<b>12.24</b>	<b>(14.36)</b>	<b>(20.39)</b>	<b>(14.36)</b>
<b>Total comprehensive income for the period/year attributable to</b>					
Owners of the parent	732.53	627.60	637.69	3,162.02	2,348.18
Non- controlling interests	(21.78)	(16.90)	(19.94)	(84.62)	(49.92)
	<b>710.75</b>	<b>610.70</b>	<b>617.75</b>	<b>3,077.40</b>	<b>2,298.26</b>
<b>Paid-up equity share capital (face value - ₹ 2 per share)</b>				<b>1,041.62</b>	<b>690.00</b>
<b>Other equity (Including Non-controlling interest)</b>				<b>20,082.35</b>	<b>17,087.97</b>
<b>Earnings per equity share (Face Value of 2 each (₹))</b>					
- Basic (₹) (not annualised except for year end figures)	<b>1.42</b>	<b>1.18</b>	<b>1.22</b>	<b>5.97</b>	<b>4.43</b>
- Diluted (₹) (not annualised except for year end figures)	<b>1.42</b>	<b>1.18</b>	<b>1.22</b>	<b>5.97</b>	<b>4.43</b>



### Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

## Notes to the audited consolidated financial results

1. The consolidated financial results for the quarter and financial year ended 31 March 2025 ("the financial results") of Suraksha Diagnostic Limited ("the Holding Company") and its subsidiary (Holding company and subsidiaries together referred to as 'the group') have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the regulations").
2. These financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 28 May 2025. These financial results for the year ended 31 March 2025 have been audited by the statutory auditor and they have issued an unmodified opinion.
3. The consolidated figures for the quarter ended 31 March 2025 are the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the third quarter of the financial year.
4. The figures for the quarter ended 31 March 2024 are presented based on the information complied by the management in accordance with Ind AS and have not been subject to review or audit by the statutory auditors or by any other auditor. However, the management has prepared the results for the said period by applying consistent accounting policies.
5. During the year ended 31 March 2025, the Holding company has completed an Initial Public Offering entirely as offer for sale of 1,91,89,330 equity shares by existing share holders with face value of ₹ 2/- and listed on both The National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange (BSE) on 06 December 2024.
6. During the year ended 31 March 2025, 0.0001% Compulsorily Convertible Preference Shares aggregating to 1,62,859 preference shares of par value ₹ 100/- each were converted into 89,55,761 equity shares of par value of ₹ 2/- each in the Holding Company.
7. During the year ended 31 March 2025, the Nomination and Remuneration Committee ("the NRC") of the Holding Company had approved grant of 2,08,164 stock options to employees under the Suraksha Employee Stock Option Scheme 2024 ("the Scheme"). The Company has accounted for these stock options in accordance with Ind AS 102 – Share-Based Payments.
8. The Group is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 – 'Operating Segments'.
9. During the quarter ended 31 March 2025, the Holding Company had entered into a Share Subscription Agreement for subscribing to 95,841 equity shares of ₹10/- each representing 16.17% of the total equity share capital of Fetomat Wellness Private Limited ('Fetomat'). Subsequent to financial year ended 31 March 2025, the Holding Company had entered into Share Purchase Agreements ('SPA's') with existing shareholders of Fetomat for acquisition of 2,77,582 equity shares of ₹10/- each representing 46.83% of the total equity share capital of Fetomat, resulting in Fetomat becoming a subsidiary of the Holding Company.
10. These financial results are also available on the Holding Company's website ([www.surakshanet.com](http://www.surakshanet.com)) and on the stock exchange websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)).
11. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.



For and on behalf of Board of Directors of  
Suraksha Diagnostic Limited

  
Somnath Chatterjee  
Chairman & Joint Managing Director  
DIN: 00137075

Place: Kolkata  
Date: 28 May 2025



## Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: [info@surakshanet.com](mailto:info@surakshanet.com) | Website: [www.surakshanet.com](http://www.surakshanet.com)

Phone: (033) 66059750 | CIN : [U85110WB2005PLC102265](https://www.mca21.gov.in/cin/U85110WB2005PLC102265)



# Suraksha

## Clinic & Diagnostics

Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India

(CIN : L85110WB2005PLC102265)

Website : www.surakshanet.com

Consolidated Statement of Assets and Liability as at 31 March 2025

(₹ in lakhs)

Particulars	As at 31 March 2025 (Audited)	As at 31 March 2024 (Audited)
<b>Assets</b>		
<b>Non-current assets</b>		
Property, plant and equipment	14,713.71	13,505.00
Capital work-in-progress	1,009.93	131.29
Right-of-use assets	7,429.02	7,540.89
Other intangible assets	150.00	107.61
Intangible Assets under Development	49.34	-
Financial assets		
Investments	100.00	-
Other financial assets	4,269.13	844.93
Non-current tax assets (net)	162.75	183.10
Other non-current assets	753.27	462.74
<b>Total non-current assets</b>	<b>28,637.14</b>	<b>22,775.56</b>
<b>Current assets</b>		
Inventories	804.89	667.83
Financial assets		
Trade receivables	1,381.23	887.49
Cash and cash equivalents	224.68	252.00
Bank balances other than cash and cash equivalents	1,785.89	5,250.27
Other financial assets	253.02	-
Other current assets	265.57	187.34
<b>Total current assets</b>	<b>4,715.28</b>	<b>7,244.93</b>
<b>Total Assets</b>	<b>33,352.42</b>	<b>30,020.49</b>
<b>Equity and Liabilities</b>		
<b>Equity</b>		
Equity share capital	1,041.62	690.00
Instruments entirely equity in nature	-	162.86
Other equity	20,082.35	17,087.97
Equity attributable to owners of the parent	21,123.97	17,940.83
Non Controlling interest	(100.86)	(26.24)
<b>Total equity</b>	<b>21,023.11</b>	<b>17,914.59</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
Borrowings	287.54	518.31
Lease liabilities	7,122.79	7,030.65
Provisions	102.22	77.13
Deferred tax liabilities (net)	545.09	538.59
<b>Total non-current liabilities</b>	<b>8,057.65</b>	<b>8,164.68</b>
<b>Current liabilities</b>		
Financial liabilities		
Borrowings	294.98	345.35
Lease liabilities	1,183.76	1,153.32
Trade payables		
Total outstanding dues of micro enterprises and small enterprises	196.74	322.61
Total outstanding dues other than above micro enterprises and small enterprises	1,167.61	1,116.64
Other financial liabilities	1,077.23	776.78
Other current liabilities	338.04	174.62
Provisions	12.52	-
Current tax liabilities (net)	0.77	51.90
<b>Total current liabilities</b>	<b>4,271.66</b>	<b>3,941.22</b>
<b>Total liabilities</b>	<b>12,329.31</b>	<b>12,105.90</b>
<b>Total equity and liabilities</b>	<b>33,352.42</b>	<b>30,020.49</b>



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265



# Suraksha

## Clinic & Diagnostics

Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India

(CIN : L85110WB2005PLC102265)

Website : www.surakshanet.com

Consolidated Statement of Cash Flows for the year ended 31 March 2025

(₹ in lakhs)

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
<b>Cash flow from operating activities</b>		
Profit before tax	4,140.53	3,145.25
Adjustments for:		
Depreciation and amortisation expenses	3,529.77	3,259.80
Finance costs	838.53	878.83
Interest on loans, deposits and IT refund	(324.52)	(322.04)
Unwinding of security deposit	(33.40)	(29.71)
Exceptional items	-	77.88
Loss on sale of property, plant and equipment	25.58	214.52
Provision for credit allowances on receivables and deposits	218.58	13.42
Security deposits written off	6.65	-
Bad debts written off	26.78	40.24
Share based payment expenses	21.12	-
Liabilities/ provisions no longer required written back	(22.97)	-
<b>Operating profit before working capital changes</b>	<b>8,426.65</b>	<b>7,278.19</b>
<b>Changes in operating assets and liabilities</b>		
Adjustments for (Increase) / decrease in operating assets		
Trade receivables	(721.22)	(473.12)
Inventories	(137.06)	(51.62)
Other financial assets	(309.41)	52.87
Other assets	(78.22)	29.68
Adjustments for increase / (decrease) in operating liabilities		
Trade payables	(51.93)	35.35
Other liabilities	163.42	50.55
Other financial liabilities	91.48	(17.70)
Provisions	10.36	4.97
<b>Cash generated from operations</b>	<b>7,394.07</b>	<b>6,909.17</b>
Income tax paid (net)	(1,058.16)	(861.04)
<b>Net cash flows generated from operating activities (A)</b>	<b>6,335.91</b>	<b>6,048.13</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant & equipment, other intangible assets and intangible asset under development (including capital work-in-progress, capital advances and capital creditors)	(4,202.40)	(4,547.24)
Proceeds from sale of property, plant & equipment	14.10	255.18
Net Redemption/(Investments) in deposits with banks	(26.03)	473.57
Investment in Company	(100.00)	-
Interest received on bank deposits	355.92	318.96
<b>Net cash flows used in investing activities (B)</b>	<b>(3,958.41)</b>	<b>(3,499.53)</b>
<b>Cash flow from financing activities</b>		
Contribution from non-controlling interests	10.00	70.26
Proceeds of borrowings	-	50.00
Repayment of borrowings	(281.14)	(586.89)
Payment of lease liabilities	(2,070.01)	(1,955.46)
Finance cost paid	(63.67)	(90.77)
<b>Net cash flows used in financing activities (C)</b>	<b>(2,404.82)</b>	<b>(2,512.86)</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>(27.32)</b>	<b>35.74</b>
Cash and cash equivalents at the beginning of the year	252.00	216.26
<b>Cash and cash equivalents at the end of the year</b>	<b>224.68</b>	<b>252.00</b>



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Annexure-2

Date: 28 May 2025

To

The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code: 544293	The Secretary The National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1 G Block Bandra -Kurla Complex, Bandra (East) Mumbai- 400 051 Scrip Symbol: SURAKSHA
---	--

Dear Sir / Ma'am,

**Sub: Declaration pursuant to the provisions of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), as amended from time to time**

Pursuant to the third proviso to Regulation 33(3)(d) of the Listing Regulations, we hereby declare and confirm that the Statutory Auditors of the Company, M/s M S K A & Associates (Firm's Registration No.: 105047W), Chartered Accountants, have issued the Auditors' Report on the audited (standalone and consolidated) financial results of the Company for the quarter and financial year ended on 31 March 2025, with **unmodified opinion**.


Kindly take the above declaration on record.

For Suraksha Diagnostic Limited



Ritu Mittal  
Joint Managing Director & CEO  
DIN: 00165886

For Suraksha Diagnostic Limited



Ravindra K S  
Group Chief Financial Officer

Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: [info@surakshanet.com](mailto:info@surakshanet.com) | Website: [www.surakshanet.com](http://www.surakshanet.com)

Phone: (033) 66059750 | CIN : [U85110WB2005PLC102265](#)

**Annexure 3**

**Details under Regulation 30 of the Listing Regulations read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 :**

Particulars Name of Auditors	Secretarial Auditor	Internal Auditor	Cost Auditor
	Mr. Pramod Agarwal, proprietor of M/s Pramod Agarwal & Co. (Firm Reg No: S2002WB057700; Peer Review: 977/2020), Practicing Company Secretaries	Ms. Rashmi Bihani, Proprietor of M/s Bihani Rashmi & Co. (Firm Registration No. 328058E) Practicing Chartered Accountants	M/s. S Chhaparia & Associates, (Firm Registration No.: 101591) Cost and Management Accountants
Reason for change viz. appointment, re-appointment, <del>resignation, removal, death or otherwise;</del>	Appointment	Re-appointment	Re-appointment
Date of appointment/re-appointment/ <del>cessation</del> (as applicable) & term of appointment/re-appointment;	<b>28 May 2025</b> Appointed to conduct secretarial audit for a term of five (5) consecutive financial years i.e. from FY 2025-26 upto FY 2029-30 in compliance with provisions of Section 204 of the Companies Act, 2013 and Regulation 24A of Listing Regulations, on the terms and conditions as mutually agreed between the Auditor and Management of the Company, subject to approval of shareholders at the ensuing Annual General Meeting.	<b>28 May 2025</b> Re-appointed to conduct an internal audit of the Company for FY 2025-26, on the terms and conditions as mutually agreed between the auditor and the management of the Company.	<b>28 May 2025</b> Re-appointed to conduct the audit of the cost records of the Company for the FY 2025-26, on the terms and conditions as mutually agreed between the auditor and management of the Company.

**Suraksha Diagnostic Limited**

**CIN: L85110WB2005PLC102265**

**Reg Office:** 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India

**E-mail:** investors@surakshanet.com | **Website:** www.surakshanet.com

**Phone:**(033) 6605 9750

<b>Brief profile (in case of appointment)</b>	<p>M/s Pramod Agarwal &amp; Co. a peer reviewed firm based in Kolkata which has over 24 years of extensive experience in corporate governance, compliance management and legal advisory services. The firm has an expertise in handling secretarial audits, company law matters, due diligence, corporate compliance management representation service and compliance frameworks for companies across various sectors including listed entities, SMEs and start-ups.</p>	<p>M/s Bihani Rashmi &amp; Co. is a Kolkata-based, professionally managed firm led by a proprietor with over 15 years of experience. The firm offers a comprehensive suite of services including audit &amp; assurance, direct and indirect taxation, law advisory, RBI and FEMA compliance, and financial advisory. Serving a diverse clientele ranging from small to large enterprises, the firm is committed to delivering quality-driven, reliable, and value-added professional services across audit, taxation, consultancy and financial domains.</p>	<p>M/s. S Chhaparia &amp; Associate, Kolkata based firm has almost over 13 years of experience in the fields of cost audits, cost compliances, cost record maintenance, cost consultancy services, corporate law, company formation and taxation. The firm handles GST matters covering a wide range of sub activities related to the profession.</p>
<b>Disclosure of relationships between Directors (in case of appointment of a Director)</b>	Not Applicable	Not Applicable	Not Applicable